Biophotonic pretreatment enhances the targeting of senile lentigines with a 694 nm QS-ruby laser

摘要

The ability of lasers to selectively destroy the melanin pigment responsible for solar/senile lentigines (SL) (age spots) without damaging the surrounding tissue makes laser therapy a preferred option for treating SL. However, laser therapies typically utilize a high energy output to achieve thermal ablation of their selective targets—and therefore can be associated with a period of recovery, healing, and down time, depending on the modality. The Kleresca? biophotonic platform, which generates fluorescent light energy (FLE), is a non‐invasive form of photobiomodulation with multiple applications